Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [5]. Offering Details - Akebia announced a public offering of 25,000,000 shares of common stock at a price of $2.00 per share, aiming to raise gross proceeds of$50.0 million before expenses [1]. - The underwriters have a 30-day option to purchase up to 3,750,000 additional shares at the public offering price [1]. - The offering is expected to close on March 21, 2025, pending customary closing conditions [1]. Underwriters - Leerink Partners and Piper Sandler & Co. are serving as joint bookrunning managers for the offering, with BTIG, LLC as the lead manager and H.C. Wainwright & Co. as co-manager [2]. Regulatory Compliance - The shares are being offered under a shelf registration statement filed with the SEC on September 3, 2024, which was declared effective on September 12, 2024 [2]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Contact Information - For inquiries regarding the offering, contact details for Leerink Partners and Piper Sandler & Co. are provided [3].